Omiganan

Drug Profile

Omiganan

Alternative Names: 1% Omiganan gel; CLS-001; CPI-226; MBI-226; MBI-594AN; MX-226; MX-594AN; Omiganan pentachloride - BioWest; Omiganan pentahydrochloride; Omiganan pentahydrochloride 1% gel; Omigard

Latest Information Update: 17 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator MIGENIX
  • Developer Cadence Pharmaceuticals; Carrus Capital Corporation; Cutanea Life Sciences
  • Class Antibacterials; Antimicrobial cationic peptides
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Catheter infections

Highest Development Phases

  • Phase III Rosacea
  • Phase II Acne vulgaris; Atopic dermatitis; Condylomata acuminata; Vulvar intraepithelial neoplasia
  • Phase I Dermatitis
  • Discontinued Catheter infections

Most Recent Events

  • 04 Jul 2017 Cutanea Life Sciences completes a phase II trial for Vulvar intraepithelial neoplasia in Netherlands (Topical) (NCT02596074)
  • 07 Mar 2017 Cutanea Life Sciences completes a phase-I trial in Healthy volunteers (Combination therapy, Monotherapy) in the Netherlands (NCT03071679)
  • 06 Feb 2017 Phase-I clinical trials in Dermatitis (In volunteers, Combination therapy, Monotherapy) in Netherlands (Topical) (NCT03071679)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top